ProMIS Neurosciences
- | Biotech or pharma, therapeutic R&D
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).
The company is currently running a clinical trial in AD with its lead antibody, PMN310 and expects clinical data in the coming 12-18 months.
Address
BostonMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}